유전성 근육질환의 유전자 치료

키워드

참고문헌 (45)

1. Hoffman EP, "Dystrophin: the protein product of the Duchenne muscular dystrophy locus", Cell, 51, pp.919~928 (1987)
2. Ng SB, "Targeted capture and massively parallel sequencing of 12 human exomes", Nature, 461, pp.272~276 (2009)
3. Sheridan C, "Gene therapy finds its niche", Nat Biotech, 29, pp.121~128 (2011)
4. Kishnani PS, "Recombinant human acid α-glucosidase: major clinical benefits in infantile-onset Pompe disease", Neurology, 68, pp.99~109 (2007)
5. Van der Ploeg AT, "A randomized study of alglucosidase alfa in late-onset Pompe’s disease", N Eng J Med, 362, pp.1396~1406 (2010)
6. Meryon E, "On granular and fatty degeneration of the voluntary muscles", Med Chir Trans, 35, pp.73~84.1 (1852)
7. Bushby K, "Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management", Lancet Neurol, 9, pp.77~93 (2010)
8. Petrof BJ, "Dystrophin protects the sarcolemma from stresses developed during muscle contraction", Proc Nat Acad Sci USA, 90, pp.3710~3714 (1993)
9. Aartsma-Rus A, "Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule", Muscle Nerve, 34, pp.135~144 (2006)
10. Aartsma-Rus A., "Overview on DMD exon skipping", Methods Mol Biol, 867, pp.97~116 (2012)
11. Aartsma-Rus A, "Overview on AON design", Methods Mol Biol, 867, pp.117~129 (2012)
12. Cartegni L, "ESEfinder: A web resource to identify exonic splicing enhancers", Nucleic Acids Res, 31, pp.3568~3571 (2003)
13. Cirak S, "Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an openlabel, phase 2, dose-escalation study", Lancet, 378, pp.595~605 (2011)
14. Goemans NM, "Systemic administration of PRO051 in Duchenne’s muscular dystrophy", N Eng J Med, 364, pp.1513~1522 (2011)
15. Mendell J,, "Results at 48 weeks of a phase IIb extension study of the exon-skipping drug eteplirsen in patients with Duchenne muscular dystrophy", 17th International Congress of the World Muscle Society (2012)
16. Aartsma-Rus A, "Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations", Hum Mutat, 30, pp.293~299 (2009)
17. Muntoni F., "The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREATNMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009", Neuromuscul Disord, 20, pp.355~362 (2010)
18. Eagle M, "Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation", Neuromuscul Disord, 12, pp.926~929 (2002)
19. Malerba A, "Long-term systemic admini stration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity", Nucleic Acid Ther, 21, pp.293~298 (2011)
20. Townsend D, "Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle", Mol Ther, 16, pp.832~835 (2008)
21. Moulton HM, "In vivo delivery of morpholino oligos by cellpenetrating peptides" (2012), Curr Pharm Des
22. 신진홍, "Recombinant adeno-associated viral vector production and purification", Methods in Molecular Biology, 798(0), pp.267~284 (2012), Humana Press, Inc.
23. 신진홍, "The evolution of heart gene delivery vectors", JOURNAL OF GENE MEDICINE, 13(10), pp.557~565, WILEY-BLACKWELL
24. Scott JM, "Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin", Neuromuscul Disord, 12, pp.23~29 (2002)
25. Liu M, "Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury", Mol Ther, 11, pp.245~256 (2005)
26. Gregorevic P, "rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice", Nat Med, 12, pp.787~789 (2006)
27. 신진홍, "Improvement of cardiac fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction", GENE THERAPY, 18(9), pp.910~919, NATURE PUBLISHING GROUP
28. Bostick B, "AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy", J Mol Cell Cardiol, 53, pp.217~222 (2012)
29. 신진홍, "A Simplified Immune Suppression Scheme Leads to Persistent Micro-dystrophin Expression in Duchenne Muscular Dystrophy Dogs", HUMAN GENE THERAPY, 23(2), pp.202~209, MARY ANN LIEBERT INC
30. Bowles DE, "Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector", Mol Ther, 20, pp.443~455 (2012)
31. Vulin A, "Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping", Mol Ther, 20, pp.2120~2133 (2012)
32. Odom GL, "Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6", Mol Ther, 19, pp.36~45 (2011)
33. Bartel MA, "Directed evolution of novel adeno-associated viruses for therapeutic gene delivery", Gene Ther, 19, pp.694~700 (2012)
34. Aartsma-Rus A, "Therapeutic exon skipping for dysferlinopathies?", Eur J Hum Genet, 18, pp.889~894 (2010)
35. Grose WE, "Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer", PLoS One, 7, pp.39233~ (2012)
36. Azakir BA, "Modular dispensability of dysferlin C2 domains reveals rational design for mini-dysferlin molecules", J Biol Chem, 287, pp.27629~27636 (2012)
37. Herson S, "A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C", Brain, 135, pp.483~492 (2012)
38. Mendell JR, "Sustained α-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D", Ann Neurol, 68, pp.629~638 (2010)
39. Buj-Bello A, "AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis", Hum Mol Genet, 17, pp.2132~2143 (2008)
40. Johnson NE, "Myotonic dystrophy: from bench to bedside", Semin Neurol, 32, pp.246~254 (2012)
41. Wheeler TM, "Targeting nuclear RNA for in vivo correction of myotonic dystrophy", Nature, 488, pp.111~115 (2012)
42. Chanchlani N., "Muscular dystrophy patients could live extra 15 years, if care standards implemented", BMJ, 340, pp.3055~ (2010)
43. Mingozzi F, "Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges", Nat Rev Genet, 12, pp.341~355 (2011)
44. Maguire AM, "Safety and efficacy of gene transfer for Leber’s congenital amaurosis", N Eng J Med, 358, pp.2240~2248 (2008)
45. Flemming A., "Regulatory watch: pioneering gene therapy on brink of approval", Nat Rev Drug Discov, 11, pp.664~ (2012)

관련 논문AI추천